EPI – Epiminder Limited
Founded in 2017 as a spin-out from the University of Melbourne, Bionics Institute and St Vincent’s Hospital Melbourne (with Cochlear as a founding partner), Epiminder built on 15+ years of academic research. Key milestones include successful Australian trials, a $16M bridge round in 2022, FDA authorization in April 2025 and a $10M pre-IPO note in early 2025.
The company generates revenue from device sales and recurring cloud-based data services. Following its $125M IPO at $1.50/share (listing 1 December 2025, $325M market cap), Epiminder will launch commercially in the US in H1 2026 via a controlled roll-out (DETECT program) at leading epilepsy centers to drive adoption and secure reimbursement. Proceeds will also fund next-gen device improvements, European regulatory submissions and expanded R&D into seizure forecasting. Cochlear remains the largest shareholder with ~36%.
It is anticipated that EPI will list on the ASX during December 2025.
